1-5 of 5
janus kinase inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Clinical Trials & Observations
Naveen Pemmaraju, Bing Z. Carter, Prithviraj Bose, Nitin Jain, Tapan M. Kadia, Guillermo Garcia-Manero, Carlos E. Bueso-Ramos, Courtney D. DiNardo, Sharon Bledsoe, Naval G. Daver, Uday Popat, Marina Y. Konopleva, Lingsha Zhou, Sherry Pierce, Zeev E. Estrov, Gautam M. Borthakur, Maro Ohanian, Wei Qiao, Lucia Masarova, Xuemei Wang, Po Yee Mak, Jorge Cortes, Elias Jabbour, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3163–3173.
https://doi.org/10.1182/bloodadvances.2020003829
Published: 2021
Journal Articles

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Clinical Trials & Observations
Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3677–3687.
https://doi.org/10.1182/bloodadvances.2020002175
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

Clinical Trials & Observations
Mark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, Leah Gehrs, Michael C. Arbushites, Ying Yan, Peter Langmuir, Nithya Srinivas, Michael Pratta, Miguel-Angel Perales, Yi-Bin Chen, Gabrielle Meyers, John F. DiPersio
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1656–1669.
https://doi.org/10.1182/bloodadvances.2019001043
Published: 2020
Includes: Supplemental data
Journal Articles

Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models

Paola Rivera-Munoz, Anouchka P. Laurent, Aurelie Siret, Cecile K. Lopez, Cathy Ignacimouttou, Melanie G. Cornejo, Olivia Bawa, Philippe Rameau, Olivier A. Bernard, Philippe Dessen, Gary D. Gilliland, Thomas Mercher, Sébastien Malinge
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1616–1627.
https://doi.org/10.1182/bloodadvances.2018016089
Published: 2018
Includes: Supplemental data
Journal Articles

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)

Clinical Trials & Observations
Geling Li, Emily Waite, Julie Wolfson
Journal: Blood Advances
Blood Adv (2017) 1 (27): 2724–2728.
https://doi.org/10.1182/bloodadvances.2017010470
Published: 2017